# A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer

> **NCT01907529** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Stage III Breast Cancer

## Interventions

- **DRUG:** docetaxel, epirubicin and cyclophosphamide
- **DRUG:** docetaxel, epirubicin and cyclophosphamide plus endostar

## Key facts

- **NCT ID:** NCT01907529
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08
- **Primary completion:** 2020-08
- **Final completion:** 2021-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2019-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01907529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01907529, "A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01907529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*